In this Pharmacy Times Peer Exchange series, expert panelists discuss key updates and clinical insights related to hyperlipidemia. The discussion focuses on the goals of lipid-lowering therapy after cardiovascular events, which focus on aggressively reducing LDL cholesterol to guideline-recommended targets to minimize recurrent risk, using stepwise strategies that prioritize statins and intensify therapy with additional agents when needed.
In this Pharmacy Times Peer Exchange series, expert oncology pharmacists discuss key updates and clinical insights related to advanced endometrial cancer. The discussion focuses on the integration of immunotherapy and ADCs into the treatment paradigm, the critical importance of biomarker testing, strategies for managing financial toxicity and irAEs, and the expanding role of the pharmacist in personalized patient advocacy and clinical pathways.
In this Pharmacy Times Peer Exchange series, expert panelists discuss key updates and clinical insights related to CDK4/6 usage in breast cancer. The discussion focuses on the latest long-term data for CDK4/6 inhibitors in early breast cancer, how to best differentiate between available CDK4/6 inhibitors in early and metastatic breast cancer, as well as real-world scenarios with CDK4/6 inhibitor utilization.
In this Pharmacy Times Peer Exchange series, expert panelists discuss key updates and clinical insights related to RSV. This discussion focuses on addressing real-world barriers to RSV vaccination, the latest guideline updates, and best practices for pharmacy workflow.
In this Pharmacy Times Peer Exchange series, expert panelists discuss key updates and clinical insights related to multiple sclerosis. The discussion focuses on enhancing recognition and monitoring of MS subtypes to support timely and accurate clinical management, applying mechanism-based therapeutic knowledge to inform treatment selection and optimize MS care and strengthening system-level care processes and the pharmacist’s role to improve MS treatment delivery and outcomes.
Panelists discuss the evolving management of metastatic breast cancer with CDK4/6 inhibitors—highlighting long-term safety, emerging clinical data, sequencing strategies, multidisciplinary care, and the growing use of digital and precision tools to enhance adherence, optimize outcomes, and individualize treatment across diverse patient populations.
Panelists discuss how pharmacists play a crucial role in optimizing CDK4/6 inhibitor therapy for patients with breast cancer through patient identification, toxicity management, adherence support, and multidisciplinary care coordination across both early-stage and metastatic treatment settings.
Panelists discuss how understanding the clinical characteristics and burden of tardive dyskinesia—especially in older adults—can inform the use of VMAT2 inhibitors, highlight ongoing care gaps, and underscore the vital role of pharmacists in optimizing therapeutic strategies and patient outcomes.
Panelists discuss best practices for maximizing respiratory syncytial virus (RSV) vaccine uptake in high-risk patients, comparing FDA-approved vaccines and emphasizing the pharmacist’s critical role in addressing hesitancy and improving access to protect vulnerable populations.
Panelists discuss how recent shifts in treatment patterns and real-world data on low-density lipoprotein cholesterol (LDL-C)–lowering therapies beyond statins can inform clinical decisions and improve outcomes for patients at very high risk post atherosclerotic cardiovascular disease (ASCVD), with an emphasis on the role of pharmacists in enhancing cholesterol management through shared decision-making.
Panelists discuss, current operational strategies and best practices for the implementation of bispecific antibody therapies, strategies for managing adverse effects associated with bispecific antibody therapies in multiple myeloma, opportunities for delivering bispecific antibody therapies for multiple myeloma in community healthcare settings, addressing challenges related to initial implementation, patient monitoring, and coordination with tertiary care centers.
Medical experts provide a comprehensive overview of pneumococcal disease in adults, discussing high-risk populations, vaccination strategies, recent vaccine developments, and current challenges, while emphasizing the importance of immunization and patient education in preventing severe outcomes and improving public health.
A panel of clinical pharmacists have a comprehensive discussion on optimizing cholesterol management in very high-risk patients with ASCVD.
A panel of experts highlights the importance of pharmacist involvement in prevention measures to combat respiratory syncytial virus (RSV) in adults.
Ryan Haumschild, PharmD, MS, MBA, leads a panel of experts in a discussion focusing on metastatic breast cancer (mBC) and early breast cancer (eBC), covering the most recent treatment guidelines, drug toxicities, and a comparative analysis of CDK4/6 inhibitors.
Expert pharmacists in myelofibrosis care share insights on emerging therapies, challenges, and their crucial role in patient advocacy and collaborative care team efforts in a comprehensive discussion.
Ryan Haumschild, PharmD, MS, MBA, leads a panel of experts in a discussion surrounding updates in CDK4/6 inhibitor use for patients with HR+/HER2- metastatic breast cancer.
A panel of experts discuss several topics pertaining to the importance of annual influenza immunizations, including the different available vaccine formulations, the ACIP recommendations, and addressing barriers related to immunizing populations yearly.
A panel of medical experts explore strategies to maximize RSV vaccination efforts in the adult patient population.
Ryan Haumschild, PharmD, MS, MBA leads a panel of medical experts in a discussion surrounding the significance of adult pneumococcal vaccination.
Experts discuss gut microbiota, current and emerging microbiome-based therapies for C difficile, and the practical ways to incorporate these treatments into your clinical practice.
Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding relapsed/refractory multiple myeloma (MM).
Key opinion leaders discuss the disease state, treatment landscape, and future considerations for treating patients with myelodysplastic syndrome (MDS).
